EHA 2024 – Chan Cheah

Chan Cheah discusses key aspects of a disease-centered treatment approach for relapsed/refractory CLL, explains how B-cell degraders, compared to BTK inhibitors, can improve management of B cell malignancies, and highlights notable results for the BTK degrader BGB-16673 in relapsed or refractory indolent non-Hodgkin lymphoma.

Here is the full EHA 2024 report.